NICE has published two new guidelines on the treatment of comorbidities diagnosed in COVID-19 patients.
The National Institute for Health and Care Excellence (NICE) has published two rapid guidelines for the treatment of patients with COVID-19.
The first relates to patients with gastrointestinal and liver conditions that require treatment with drugs that affect the immune system. The new guidance recommends that patients should continue taking drugs that affect the immune response, but if a patient develops COVID-19, they should seek advice from their clinical team.
The second guideline relates to patients with suspected acute myocardial injury who also have known or suspected COVID-19. NICE highlights that statistics from Italy show that almost 10% of patients dying of COVID-19 suffered from acute myocardial injury, and recommends monitoring of blood pressure, heart rate, fluid balance, and continuous electrocardiogram.
NICE’s press release is available here.